PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES

Nirmish Shah(Duke University), Abdullah Kutlar(Augusta University), Brandon M. Hardesty(Indiana Hemophilia and Thrombosis Center), Walter K. Kraft(Thomas Jefferson University), Vince D. Cataldo(Louisiana State University), Maureen Achebe(Beth Israel Deaconess Medical Center), Jincy Paulose, Dramane I. Lainé(Oaklands Hospital), D Purkayastha(Oaklands Hospital), Ralph V. Boccia(Center for Cancer and Blood Disorders), Menaka Bhor(Novartis (United States))
Value in Health
May 1, 2019
10.1016/j.jval.2019.04.1637
Cited by 3

Related Papers

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
|The Lancet Oncology|2013|387
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386